{"entity":{"id":"nct06938503","kind":"trial","name":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of gemcitabine + nab-paclitaxel and nimotuzumab in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","summary":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT06938503 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 48 participants, started 2025-04-21 and due to reach its primary completion in 2028-04-25. Interventions recorded: AG regimen; Nimotuzumab. Conditions listed: Pancreatic Cancer, Adult. Primary outcome: overall survival (OS). Pancreatic eligibility wording from the registry: \"Histologically or cytologically confirmed pancreatic cancer;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06938503","url":"https://clinicaltrials.gov/study/NCT06938503"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","irreversible-electroporation"],"targets":[],"drugs":["gemcitabine-nab-paclitaxel","nimotuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06938503","phase":"2","setting":"A Prospective, Single-Arm Study of Nab-paclitaxel/Gemcitabine Combined With Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","sponsor":"Tianjin Medical University Cancer Institute and Hospital","participation":[{"nct":"NCT06938503","source":"https://clinicaltrials.gov/study/NCT06938503","fetchedAt":"2026-10-07T16:55:18.467Z","studySha256":"5ecfd43672b1a873f205e061909aa764ca17f0a39416c6a0e2f33cf07bdc83dc","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2025-04-22","leadSponsor":"Tianjin Medical University Cancer Institute and Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":48,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2025-04-21","startedType":"estimated","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06938503/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"irreversible-electroporation","kind":"technology","name":"Irreversible electroporation (NanoKnife)","route":"/technologies/irreversible-electroporation/"}],"drug":[{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"},{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}